TTrialPathMatch Me to Trials
← Back to trials
RecruitingHepatic Encephalopathy

Late Evening and Early Morning Protein Supplement to Reduce Readmissions for Hepatic Encephalopathy

Eligible age

18–75 yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

Readmission rates for patients with hepatic encephalopathy due to end stage liver disease are high. Hyperammonemia contributes significantly to encephalopathy and occurs because of impaired hepatic ureagenesis and increased skeletal muscle proteolysis. We propose a randomized, 6-month nutritional intervention in cirrhotic patients who have had at least 1 admission for hepatic encephalopathy within the last 6 months. We hypothesize that a combination of late evening and early morning protein supplement (Ensure Enlive) will decrease recurrent hepatic encephalopathy and consequent readmission rates by lowering skeletal muscle proteolysis and improved lean body mass.

Sponsor: The Cleveland Clinic

You may qualify if…

  • ✓ \> 18 years of age
  • ✓ cirrhosis diagnosed by clinical history and liver biopsy and/or clinical, biochemical and imaging evidence of cirrhosis
  • ✓ at least 1 hospitalization for documented HE within the last 12 months.
  • ✓ abdominal CT scan anytime in the past

You may not qualify if…

  • ✕ Patients with MELD score \> 35
  • ✕ end stage organ failure (major dysfunction requiring organ support)
  • ✕ kidney injury defined by a creatinine \> 2 mg/dl or rise in creatinine by 0.5 gm/dl from baseline that is unresponsive to withholding diuretics and intravenous albumin administration (1 gm/kg up to 100 gm/day)
  • ✕ active malignancy
  • ✕ uncontrolled diabetes mellitus with A1c\>9.5 (to avoid altered muscle protein metabolism
  • ✕ medications (anabolic steroids, corticosteroids) that affect skeletal muscle mass
  • ✕ recent gastrointestinal surgery within past 12 months
  • ✕ ongoing infection (positive blood or other body fluid cultures)

Where it's recruiting

Ohio

Cleveland

Source: ClinicalTrials.gov · NCT04096014 · last updated 2026-09-25